Latest News

Earlier this month, Stewart Information Services’ board declared a first-quarter 2026 cash dividend of US$0.525 per share, while director Bradley C. Allen Jr. purchased 1,000 shares on March 10, 2026, adding to his accumulated insider buying over the past year. Together, the sustained dividend and director share purchase highlight active insider participation and a board signaling confidence in the company’s cash generation and operations. Next, we’ll examine how the reaffirmed dividend...

In recent days, analysts at Canaccord Genuity and Stifel reiterated positive views on Artivion, highlighting the aortic disease pipeline and particularly the NEXUS stent graft system after one-year trial data showed strong sealing and low endoleak rates, with physicians indicating plans to adopt the device if it receives FDA approval. This combination of supportive clinical evidence and physician interest underscores how Artivion’s pipeline products could strengthen its position in treating...

Why laser dicing issues put Enovix (ENVX) in the spotlight Enovix (ENVX) has been drawing attention after several analysts flagged laser dicing problems that are affecting production yields, slowing battery qualification for a key customer and prompting reduced expectations despite continued positive ratings. See our latest analysis for Enovix. Those manufacturing concerns have been reflected in Enovix’s share price, with a 30 day share price return showing a 19.41% decline and a 90 day share...

Alcoa (AA) has moved to sell ten closed industrial sites to data center firms, repurposing idle smelter real estate that sits close to power sources and linking its traditional aluminum business to computing demand. See our latest analysis for Alcoa. Alcoa's stock has seen a sharp shift in sentiment over recent months, with a 37.82% 90 day share price return and a 91.78% 1 year total shareholder return, even after a 3.55% one day pullback to US$63.59, as investors weigh data center land...

Tango Therapeutics (TNGX) is back in focus after reporting fourth quarter and full year 2025 results, outlining a funding runway beyond 2028, and signing a new clinical trial collaboration with Erasca for difficult cancers. See our latest analysis for Tango Therapeutics. The earnings update, extended funding runway and new Erasca collaboration appear to have coincided with building momentum, with the 30 day share price return of 37.19% and year to date share price return of 93.73% sitting...

ANZ Group Holdings (ASX:ANZ) is back in focus after announcing that Tammy Medard will become Group Executive, Business & Private Bank, effective 1 May 2026, in a key leadership move tied directly to its 2030 strategy. See our latest analysis for ANZ Group Holdings. At a share price of A$37.2, ANZ Group Holdings has delivered a 3.88% 90 day share price return and a 38.30% 1 year total shareholder return. This suggests that momentum has been supported by executive changes, the upcoming debt...

If you are wondering whether e.l.f. Beauty's share price still reflects its true worth after a strong multi year run, looking closely at its valuation can help put the current price into context. The stock last closed at US$73.41, with returns of an 11% decline over the past 7 days, a 4.4% decline over 30 days, a 5.7% decline year to date, a 7.7% gain over 1 year, 1.3% over 3 years, and a very large gain over 5 years. Recent price moves sit against a backdrop of ongoing interest in e.l.f...

If you are wondering whether Chemed is attractively priced after a tough stretch, this article walks through what the current share price may be implying about its value. The stock closed at US$401.87, with returns of a 1.5% decline over 7 days, 13.2% decline over 30 days, 5.2% decline year to date, 32.5% decline over 1 year, 21.0% decline over 3 years and 9.6% decline over 5 years. This performance may change how investors think about its risk and return trade off. Recent coverage around...

In recent days, Magnolia Oil & Gas reported an 11% increase in proved developed producing reserves, fourth-quarter net income of US$71.4 million, and year-on-year production growth to 103,800 barrels of oil equivalent per day. At the same time, insider share sales and a new 52-week high coincided with analysts highlighting Magnolia’s stronger reserve base and operational efficiency amid shifting geopolitical conditions for oil markets. We’ll now examine how Magnolia’s improved reserves and...

Lazard (LAZ) has been caught in a sector wide selloff, as geopolitical tensions, higher crude prices, and JPMorgan’s lending pullback to private credit providers have fueled liquidity worries and pressured financial stocks. See our latest analysis for Lazard. At a share price of US$40.53, Lazard has seen a 1 day share price return of 0.37% decline, a 7 day share price return of 9.21% decline, and a 30 day share price return of 26.03% decline. Its 1 year total shareholder return of 5.99%...

Why Warner Bros. Discovery Stock Is on Investors’ Radar Warner Bros. Discovery (WBD) continues to attract attention as investors weigh its recent share performance, with the stock showing a 1 day return of 1.06% and a past 3 months return of 9.47%. Those moves sit alongside a reported US$37.3b in revenue and US$728m in net income. This has prompted many to reassess how the media group’s Streaming, Studios, and Global Linear Networks segments stack up at the current US$27.14 share price. See...

What recent performance suggests for Parex Resources (TSX:PXT) Parex Resources (TSX:PXT) has quietly put up strong total returns, with the share price up about 24% over the past month and roughly 45% over the past 3 months. Over the past year, total return sits near 110%, while the year to date move is close to 39%. Those numbers naturally raise questions about what is already priced in and where value might still exist. See our latest analysis for Parex Resources. With the share price now at...

In March 2026, Bumble reported fourth-quarter 2025 results that exceeded revenue and earnings expectations, issued first-quarter 2026 revenue guidance of US$209 million to US$213 million (including US$171 million to US$174 million from the Bumble app), and highlighted stronger profitability despite fewer paying users. The company also unveiled an AI-powered overhaul, including its Bee model, the Dates assistant and the upcoming Bumble 2.0 cloud-native platform, aiming to improve user...

Why Perrigo’s UBS conference appearance is drawing fresh attention Perrigo (PRGO) is set to present at the UBS Global Consumer and Retail Conference in New York on March 11, 2026, with President and CEO Patrick Lockwood-Taylor scheduled to speak. The event has put a fresh spotlight on the stock, as investors look for updated commentary on Perrigo’s over the counter health and wellness portfolio, recent financial results, and how management is thinking about capital allocation. See our latest...

Aptiv’s board has approved the spin-off of its Electrical Distribution Systems business into a new, independent public company called Versigent, and its subsidiary Aptiv Swiss Holdings has launched a cash tender offer of up to US$1.35 billion for outstanding notes, contingent on completing the separation and receiving at least US$1.70 billion in special dividends from Versigent. By pairing the Versigent spin-off with new bond issuances and a sizable tender offer, Aptiv is actively reshaping...

Rheinmetall plans to become a pure-play defense group by exiting its civilian automotive operations and acquiring Naval Vessels Luerssen. The company is guiding for its order backlog to more than double to €135b by 2026, supported by higher European and NATO defense demand. This move marks a major shift in Rheinmetall’s business mix toward both land and maritime defense systems. XTRA:RHM is now positioned at the center of Europe’s defense build up, with a current share price of €1,592.5 and...

In early March 2026, a federal Medicare regulator warned Elevance Health that it may face intermediate sanctions over alleged noncompliance with risk‑adjustment and data submission rules, potentially halting new enrollments for certain Medicare Advantage prescription drug plans if issues are not resolved. At the same time, Elevance Health reaffirmed its 2026 earnings and benefit expense guidance and expanded clinical partnerships such as Myomo’s orthotic device coverage, highlighting a...

In March 2026, Palantir Technologies and partners including Ondas, World View, GE Aerospace, Centrus Energy, LG CNS, NVIDIA, and Polymarket announced a wave of collaborations applying Palantir’s AI platforms to defense, aerospace, industrial operations, sovereign AI data centers, and sports integrity monitoring. These agreements highlight Palantir’s push to embed its Artificial Intelligence Platform and related software as core infrastructure across high-stakes sectors, from military...

Arafura Rare Earths (ASX:ARU) is back in focus after a series of project and funding updates, including a land compensation agreement for its Nolans project and an application to quote 23.4 million new shares on the ASX. See our latest analysis for Arafura Rare Earths. These project updates and the move to quote 23.4 million new shares come at a time when momentum in the stock has picked up, with a 30 day share price return of 26.67% and a 1 year total shareholder return of 72.73%, even...

If you are looking at Humana and wondering whether the recent share price puts it in bargain territory or not, it helps to start with the facts behind the current valuation story. Humana's share price most recently closed at US$165.43, with returns of a 7.7% decline over 7 days, a 5.7% decline over 30 days, a 37.5% decline year to date, a 33.7% decline over 1 year, a 65.5% decline over 3 years, and a 57.7% decline over 5 years. Recent headlines around Humana have focused on how the share...

In recent weeks, Merit Medical Systems faced a shift in Wall Street opinion when Wells Fargo downgraded its rating, prompting a period of sustained institutional selling despite no major operational changes. What stands out is that the company’s underlying operations and financial health remain solid, suggesting investor sentiment has moved more than the business fundamentals. We’ll now explore how Wells Fargo’s downgrade and the resulting sentiment shift may influence Merit Medical...

If you are wondering whether BYD at HK$96.75 is a bargain or a value trap, you are not alone. A closer look at how its price lines up with fundamentals can help you frame that question. The stock has returned 2.2% over the last 7 days, but is sitting on a 2.4% decline over 30 days, a 2.0% decline year to date and a 23.9% decline over 1 year, compared with gains of 46.0% over 3 years and 62.2% over 5 years. Recent headlines around BYD have focused on its position in the electric vehicle and...

Westpac Banking (ASX:WBC) has been drawing attention after recent share price moves, with the stock last closing at A$40.99. That has investors taking a closer look at its latest financial profile and valuation. See our latest analysis for Westpac Banking. Recent moves have been relatively steady, with a 1 day share price return of 1.11% and a 90 day share price return of 5.64%. The 1 year total shareholder return of 44.59% and 3 year total shareholder return of around 2.3x indicate stronger...

Weather hit, guidance cut: why Vail Resorts stock is back in focus Vail Resorts (MTN) is under the spotlight after one of the weakest snowfall seasons in over 30 years led to fewer skier visits, softer revenue across business lines, and a cut to 2026 earnings guidance. See our latest analysis for Vail Resorts. Those weather headwinds and the cut to 2026 guidance have weighed on sentiment, with a 90 day share price return of 18.56% and a 1 year total shareholder return of 12.46% in decline...